Shu-Chih Chen
Fondateur chez ATOSSA THERAPEUTICS, INC.
Fortune : - $ au 30/06/2024
Postes actifs de Shu-Chih Chen
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/04/2009 | - |
| Fondateur | 01/12/2008 | - | |
| Directeur Technique/Scientifique/R&D | 01/04/2010 | - |
Historique de carrière de Shu-Chih Chen
Anciens postes connus de Shu-Chih Chen
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| SC2Q Consulting Co. | Fondateur | 01/01/2006 | 01/01/2008 |
| President | - | 01/01/2008 | |
MDRNA, Inc.
 MDRNA, Inc. Miscellaneous Commercial ServicesCommercial Services MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY. | Directeur/Membre du Conseil | 01/01/2002 | 01/01/2006 |
| Ensisheim Partners LLC | President | 01/01/2008 | - |
| National Yang Ming University | Corporate Officer/Principal | - | - |
Formation de Shu-Chih Chen
| Michigan State University | Doctorate Degree |
| National Yang Ming University | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 6 |
| Taïwan | 2 |
Opérationnelle
| Director/Board Member | 2 |
| Founder | 2 |
| President | 2 |
Sectorielle
| Consumer Services | 3 |
| Health Technology | 2 |
| Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ATOSSA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
| SC2Q Consulting Co. | |
| Ensisheim Partners LLC | |
MDRNA, Inc.
MDRNA, Inc. Miscellaneous Commercial ServicesCommercial Services MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY. | Commercial Services |
- Bourse
- Insiders
- Shu-Chih Chen
- Expérience
